放射性药物联合双膦酸盐类药物治疗肿瘤骨转移研究现状

刘康其 周海中

引用本文:
Citation:

放射性药物联合双膦酸盐类药物治疗肿瘤骨转移研究现状

    通讯作者: 周海中, 769096345@qq.com
  • 中图分类号: TB 133

Concurrent use of radionuclides and bisphosphonates in bone metastasis: a review

    Corresponding author: Haizhong Zhou, 769096345@qq.com
  • CLC number: TB 133

  • 摘要: 骨转移是恶性肿瘤远处转移最常见类型之一,其发生率仅次于肺转移和肝转移。前列腺癌、乳腺癌以及肺癌是骨转移发生率最高的恶性肿瘤,近70%的乳腺癌或前列腺癌发展到晚期都会发生骨转移。肿瘤骨转移往往会引起疼痛、骨折以及高钙血症等不适,从而严重影响患者的生活质量。肿瘤骨转移目前尚无标准的规范化治疗方案,往往需要结合多种治疗方法进行综合治疗。双膦酸盐类药物和放射性药物是目前临床治疗多发骨转移广泛应用的药物,对于两者的应用,目前较为普遍的还是单药治疗,关于两者是否应该联合应用的问题一直存在争议。笔者系统回顾了近年来关于放射性药物联合双膦酸盐类药物治疗的相关研究。
  • [1] Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity[J]. J Cell Biochem, 2004, 91(4): 718−729. DOI: 10.1002/jcb.10662.
    [2] Reddi AH, Roodman D, Freeman C, et al. Mechanisms of tumor metastasis to the bone: challenges and opportunities[J]. J Bone Miner Res, 2003, 18(2): 190−194. DOI: 10.1359/jbmr.2003.18.2.190.
    [3] Wang YP, Tao H, Yu XY, et al. Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer[J]. Clin Lung Cancer, 2013, 14(3): 254−260. DOI: 10.1016/j.cllc.2012.09.001.
    [4] Yamada K, Yoshimura M, Kaise H, et al. Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases[J]. Exp Ther Med, 2012, 3(2): 226−230. DOI: 10.3892/etm.2011.405.
    [5] 赵卫威, 解朋. 89Sr治疗前列腺癌骨转移的研究进展[J]. 中华男科学杂志, 2010, 16(3): 269−272. DOI: 10.13263/j.cnki.nja.2010.03.026.
    Zhao WW, Xie P. Strontium-89 for bone metastases from prostate cancer: an update[J]. Nat J Androl, 2010, 16(3): 269−272. DOI: 10.13263/j.cnki.nja.2010.03.026.
    [6] Auclerc G, Antoine EC, Cajfinger F, et al. Management of advanced prostate cancer[J]. Oncologist, 2000, 5(1): 36−44. DOI: 10.1634/theoncologist.5−1−36.
    [7] Lewington VJ. Bone-seeking radionuclides for therapy[J]. J Nucl Med, 2005, 46(Suppl 1): S38−47.
    [8] Marcus CS, Saeed S, Mlikotic A, et al. Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP[J]. Clin Nucl Med, 2002, 27(6): 427−430. DOI: 10.1097/00003072−200206000−00008.